1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, endo,exo-
RTECS #
IO2100000
CAS #
Updated
September 2018
Molecular Weight
364.90
Molecular Formula
C12H8Cl6
Synonyms
1,2,3,4,10,10-Hexachloro-1,4,4a,5,8,8a-hexahydro-1,4,5,8-dimethanonaphthalene
1,2,3,4,10,10-Hexachloro-1,4,4a,5,8,8a-hexahydro-1,4-endo-exo-5,8-dimethanonaphthalene
1,2,3,4,10,10-Hexachloro-1,4,4a,5,8,8a-hexahydro-exo-1,4-endo-5,8-dimethanonaphthalene
Aldrex
Aldrex 30
Aldrex 30 E.C.
Aldrin
Aldrin (ACGIH:OSHA)
Aldrine (French)
Aldrite
Aldrosol
Altox
Compound 118
ENT 15,949
Hexachlorohexahydro-endo-exo-dimethanonaphthalene
HHDN
Kortofin
Latka 118 (Czech)
NCI-C00044
Octalene
RCRA waste number P004
SD 2794
Seedrin
Tatuzinho
1,2,3,4,10,10-Hexachloro-1,4,4a,5,8,8a-hexahydro-1,4-endo-exo-5,8-dimethanonaphthalene
1,2,3,4,10,10-Hexachloro-1,4,4a,5,8,8a-hexahydro-exo-1,4-endo-5,8-dimethanonaphthalene
Aldrex
Aldrex 30
Aldrex 30 E.C.
Aldrin
Aldrin (ACGIH:OSHA)
Aldrine (French)
Aldrite
Aldrosol
Altox
Compound 118
ENT 15,949
Hexachlorohexahydro-endo-exo-dimethanonaphthalene
HHDN
Kortofin
Latka 118 (Czech)
NCI-C00044
Octalene
RCRA waste number P004
SD 2794
Seedrin
Tatuzinho
Mutation Data and Reference
System Test | Route/Organism/Tissue | Dose | Reference |
---|---|---|---|
Cytogenetic Analysis | lymphocyte/human | 19125 µg/L | MUREAV 31,103,1975 |
Cytogenetic Analysis | leukocyte/human | 19125 µg/L | PHTHDT 6,147,1979 |
Cytogenetic Analysis | intraperitoneal/rat | 9560 µg/kg | PHTHDT 6,147,1979 |
Cytogenetic Analysis | intraperitoneal/mouse | 9560 µg/kg | PHTHDT 6,147,1979 |
Cytogenetic Analysis | oral/mouse | 13 mg/kg | IMSCE2 14,1125,1986 |
DNA Damage | liver/rat | 300 µmol/L | SinJF# 26OCT1982 |
DNA inhibition | other cell types/rat | 100 mg/L | ARTODN 45,101,1980 |
DNA inhibition | lymphocyte/human | 100 mg/L | ARTODN 45,101,1980 |
micronucleus test | intraperitoneal/other fish | 3000 ppm | NULSAK 28,176,1985 |
mutation in microorganisms | /Saccharomyes cerevisiae | 5 ppm (-enzymatic activation step) | RSTUDV 6,161,1976 |
other mutation test systems | oral/mouse | 10 mg/kg | MUREAV 343,157,1995 |
Unscheduled DNA Synthesis | fibroblast/human | 1 µmol/L | MUREAV 42,161,1977 |
Unscheduled DNA Synthesis | oral/mouse | 11 µmol/kg | CRNGDP 8,1433,1987 |
Reproductive Effects Data and References
Route/Organism | Dose | Effect | Reference |
---|---|---|---|
intraperitoneal/rat | 1950 µg/kg (13D male) | Reproductive: Other effects on male Endocrine: Androgenic | ANDRDQ 20,472,1988 |
intraperitoneal/rat | 3900 µg/kg (26D male) | Reproductive: Paternal effects: Prostate, seminal vesicle, Cowper's gland, accessory glands | ANDRDQ 20,472,1988 |
oral/mouse | 25 mg/kg (9D pregnant) | Reproductive: Specific developmental abnormalities: Eye, ear Reproductive: Specific developmental abnormalities: Musculoskeletal system | TJADAB 9,11,1974 |
oral/Dog | 73 mg/kg (44W prior to copulation/1-8W pregnant) | Reproductive: Effects on newborn: Live birth index (Litter size (e.g., # fetuses per litter; measured after birth) | JAVMA4 123,28,1953 |
oral/hamster | 50 mg/kg (7D pregnant) | Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Effects on embryo or fetus: Fetal death | TJADAB 9,11,1974 |
oral/hamster | 50 mg/kg (7D pregnant) | Reproductive: Specific developmental abnormalities: Eye, ear Reproductive: Specific developmental abnormalities: Musculoskeletal system Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue) | TJADAB 9,11,1974 |
subcutaneous/rat | 10 mg/kg (2D prior to copulation) | Reproductive: Maternal effects: Uterus, cervix, vagina | ENVRAL 16,131,1978 |
subcutaneous/rat | 22 mg/kg (1-22D pregnant) | Reproductive: Effects on newborn: Behavioral | BJMRDK 22,979,1989 |
subcutaneous/rat | 21 mg/kg (21D after birth) | Reproductive: Effects on newborn: Biochemical and metabolic Reproductive: Effects on newborn: Behavioral | BJMRDK 22,979,1989 |
Tumorigenic Data and References
Route/Organism | Dose | Effect | Reference |
---|---|---|---|
oral/mouse | lowest published toxic dose: 270 mg/kg/80W- intermittent | Tumorigenic: Carcinogenic by RTECS criteria Liver: Tumors | NCITR* NCI-TR-21,1978 |
oral/mouse | toxic dose: 540 mg/kg/80W- intermittent | Tumorigenic: Carcinogenic by RTECS criteria Liver: Tumors | NCITR* NCI-TR-21,1978 |
oral/rat | toxic dose: 188 mg/kg/2Y- continuous | Tumorigenic: Equivocal tumorigenic agent by RTECS criteria Liver: Multiple effects Lung, Thorax, or Respiration: Other changes | TXAPA9 11,88,1967 |
oral/rat | lowest published toxic dose: 200 mg/kg/2Y- continuous | Tumorigenic: Neoplastic by RTECS criteria Lung, Thorax, or Respiration: Tumors Skin and Appendages: Tumors | FCTXAV 2,551,1964 |
Acute Toxicity Data and References
Route/Organism | Dose | Effect | Reference |
---|---|---|---|
In Vitro/ctd | Inhibitor Concentration Low: 0.1 µg/L/72H | Endocrine: Androgenic Endocrine: Estrogenic | TXAPA9 285,23,2015 |
In Vitro/cte | Inhibitor Concentration Low: 10 µg/L/24H | Reproductive: Other effects on female | TXAPA9 285,23,2015 |
In Vitro/Mouse, fibroblast | Inhibitor Concentration (10 percent kill): 33 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc. | TIVIEQ 2,1,1988 |
In Vitro/Mouse, fibroblast | Inhibitor Concentration (50 percent kill): 61 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc. | TIVIEQ 2,1,1988 |
In Vitro/Mouse, fibroblast | Inhibitor Concentration (10 percent kill): 14 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 2,1,1988 |
In Vitro/Mouse, fibroblast | Inhibitor Concentration (50 percent kill): 55 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 2,1,1988 |
inhalation/cat | lethal concentration (50 percent kill): 20 mg/m3 | VCVGH* -,567,1990 | |
inhalation/mouse | lethal concentration (50 percent kill): 3 mg/m3 | VCVGH* -,567,1990 | |
inhalation/rat | lethal concentration (50 percent kill): 90 mg/m3 | VCVGH* -,567,1990 | |
inhalation/rat | Lowest published lethal concentration: 5800 µg/m3/4H | 85GMAT -,73,1982 | |
intracerebral/mouse | lethal dose (50 percent kill): 4 mg/kg | Behavioral: Convulsions or effect on seizure threshold | TOLED5 60,289,1992 |
intraperitoneal/Dog | lethal dose (50 percent kill): 1999 mg/kg | Liver: Liver function tests impaired | TXAPA9 10,119,1967 |
intraperitoneal/mouse | lethal dose (50 percent kill): 50 mg/kg | SOGEBZ 2,80,1966 | |
intraperitoneal/rat | lethal dose (50 percent kill): 150 mg/kg | TXAPA9 11,302,1967 | |
intravenous/mouse | lethal dose (50 percent kill): 21 mg/kg | 32ZDAL -,52,1970 | |
oral/cat | lowest published lethal dose: 15 mg/kg | Lung, Thorax, or Respiration: Chronic pulmonary edema or congestion Liver: Fatty liver degeneration Kidney, Ureter, and Bladder: Other changes | CVETAA 2,71,1958 |
oral/chicken | lethal dose (50 percent kill): 10 mg/kg | Behavioral: Convulsions or effect on seizure threshold Behavioral: Excitement Behavioral: Change in motor activity (specific assay) | JEENAI 45,121,1952 |
oral/child | lowest published lethal dose: 1250 µg/kg | 34ZIAG -,82,1969 | |
oral/Dog | lethal dose (50 percent kill): 65 mg/kg | PCOC** -,7,1966 | |
oral/duck | lethal dose (50 percent kill): 520 mg/kg | DOEAAH 35,25,1979 | |
oral/guinea pig | lethal dose (50 percent kill): 33 mg/kg | PCOC** -,7,1966 | |
oral/hamster | lethal dose (50 percent kill): 100 mg/kg | TJADAB 9,11,1974 | |
oral/human | lowest published toxic dose: 14 mg/kg | Behavioral: Tremor Behavioral: Excitement Gastrointestinal: Nausea or vomiting | 34ZIAG -,82,1969 |
oral/mouse | lethal dose (50 percent kill): 18 mg/kg | VCVGH* -,567,1990 | |
oral/pigeon | lethal dose (50 percent kill): 56200 µg/kg | ASTTA8 (680),157,1979 | |
oral/quail | lethal dose (50 percent kill): 42100 µg/kg | ASTTA8 (680),157,1979 | |
oral/rabbit | lethal dose (50 percent kill): 50 mg/kg | PCOC** -,7,1966 | |
oral/rat | lethal dose (50 percent kill): 38 mg/kg | HBPTO* 2,1136,2001 | |
oral/wild bird | lethal dose (50 percent kill): 7200 µg/kg | TXAPA9 21,315,1972 | |
skin/cat | lowest published lethal dose: 75 mg/kg | Lung, Thorax, or Respiration: Chronic pulmonary edema or congestion Liver: Fatty liver degeneration Kidney, Ureter, and Bladder: Other changes | CVETAA 2,71,1958 |
skin/cat | lethal dose (50 percent kill): 75 mg/kg | VCVGH* -,567,1990 | |
skin/rabbit | lethal dose (50 percent kill): 15 mg/kg | Olfaction: Other olfaction effects Behavioral: Convulsions or effect on seizure threshold Behavioral: Excitement | JEENAI 46,702,1953 |
skin/rabbit | lethal dose (50 percent kill): 84 mg/kg | VCVGH* -,567,1990 | |
skin/rat | lethal dose (50 percent kill): 98 mg/kg | TXAPA9 14,515,1969 | |
subcutaneous/rabbit | lowest published lethal dose: 100 mg/kg | 85GMAT -,73,1982 | |
subcutaneous/rat | lethal dose (50 percent kill): 62 mg/kg | 85GMAT -,73,1982 | |
unreported route/Dog | lowest published lethal dose: 95 mg/kg | AMIHBC 3,64,1951 | |
unreported route/mammal (species unspecified) | lethal dose (50 percent kill): 40 mg/kg | 30ZDA9 -,62,1971 |
Other Multiple Dose Data and References
Route/Organism | Dose | Effect | Reference |
---|---|---|---|
intramuscular/rat | lowest published toxic dose: 290 mg/kg/58D- intermittent | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other esterases | AMIHBC 9,306,1954 |
intraperitoneal/rat | lowest published toxic dose: 1950 µg/kg/13D- intermittent | Reproductive: Paternal effects: Testes, epididymis, sperm duct Reproductive: Paternal effects: Prostate, seminal vesicle, Cowper's gland, accessory glands Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Dehydrogenases | ENVPAF 51,87,1988 |
intraperitoneal/rat | lowest published toxic dose: 3900 µg/kg/26D- intermittent | Related to Chronic Data: Changes in testicular weight | ENVPAF 51,87,1988 |
intraperitoneal/rat | lowest published toxic dose: 1950 mg/kg/13D- intermittent | Endocrine: Change in LH Endocrine: Androgenic Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) | JOENAK 119,75,1988 |
intraperitoneal/rat | lowest published toxic dose: 3900 mg/kg/26D- intermittent | Endocrine: Change in gonadotropins | JOENAK 119,75,1988 |
oral/cat | lowest published toxic dose: 91500 µg/kg/61D- intermittent | Peripheral Nerve and Sensation: Spastic paralysis with/without sensory change Behavioral: Convulsions or effect on seizure threshold Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | CVETAA 2,71,1958 |
oral/Dog | lowest published toxic dose: 81120 µg/kg/68W- intermittent | Liver: Changes in liver weight | JAFCAU 3,402,1955 |
oral/mouse | lowest published toxic dose: 66 mg/kg/3D- intermittent | Liver: Hepatitis (hepatocellular necrosis), zonal Liver: Other changes Liver: Changes in liver weight | TXCYAC 249,176,2008 |
oral/rat | lowest published toxic dose: 9100 µg/kg/26W- intermittent | Endocrine: Other changes Blood: Other changes | GISAAA 31(4),13,1966 |
oral/rat | lowest published toxic dose: 109 mg/kg/2Y- continuous | Liver: Changes in liver weight | JAFCAU 3,402,1955 |
oral/rat | lowest published toxic dose: 348 mg/kg/58D- continuous | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other esterases | AMIHBC 9,306,1954 |
Reviews
Organization | Standard | Reference |
---|---|---|
American Conference of Governmental Industrial Hygienists (ACGIH) | Threshold Limit Value-time-weighted average 0.05 mg/m3 (inhal, vapor, skin) | DTLVS* TLV/BEI,2013 |
American Conference of Governmental Industrial Hygienists (ACGIH) | Threshold Limit Value-Confirmed animal carcinogen | DTLVS* TLV/BEI,2013 |
International Agency for Research on Cancer (IARC) | Cancer Review:Animal Limited Evidence | IMSUDL 7,88,1987 |
International Agency for Research on Cancer (IARC) | Cancer Review:Human Inadequate Evidence | IMEMDT 5,25,1974 |
International Agency for Research on Cancer (IARC) | Cancer Review:Group 3 | IMSUDL 7,88,1987 |
TOXICOLOGY REVIEW | ENVRAL 7,243,1974 | |
TOXICOLOGY REVIEW | RREVAH 48,141,1973 | |
TOXICOLOGY REVIEW | RREVAH 56,107,1975 | |
TOXICOLOGY REVIEW | DTTIAF 80,485,1973 | |
TOXICOLOGY REVIEW | BNYMAM 54,413,1978 | |
TOXICOLOGY REVIEW | 85CVA2 5,250,1970 | |
TOXICOLOGY REVIEW | CTOXAO 13,231,1978 | |
TOXICOLOGY REVIEW | EESADV 1,89,1977 | |
TOXICOLOGY REVIEW | TXAPA9 10,613,1967 | |
TOXICOLOGY REVIEW | NTIS** PB82-219007 | |
TOXICOLOGY REVIEW | 26UZAB 6,149,1968/1970 | |
TOXICOLOGY REVIEW | EVHPAZ 109(Suppl 1),113,2001 | |
TOXICOLOGY REVIEW | TOLED5 127,101,2002 | |
TOXICOLOGY REVIEW | MUREAV 567,109,2004 | |
TOXICOLOGY REVIEW | MUTAEX 21,93,2006 | |
TOXICOLOGY REVIEW | ENTOX* -,66,2005 | |
TOXICOLOGY REVIEW | MUREAV 584,1,2005 | |
TOXICOLOGY REVIEW | ENTOX* -,334,2005 | |
TOXICOLOGY REVIEW | HETOEA 25,413,2006 | |
TOXICOLOGY REVIEW | MUREAV 654,114,2008 | |
TOXICOLOGY REVIEW | TPHSDY 29,322,2008 | |
TOXICOLOGY REVIEW | FCTOD7 46,813,2008 | |
TOXICOLOGY REVIEW | MUREAV 674,36,2009 | |
TOXICOLOGY REVIEW | MUREAV 760,1,2014 | |
TOXICOLOGY REVIEW | MUREAV 769,34,2014 | |
TOXICOLOGY REVIEW | TOLED5 201,152,2011 | |
TOXICOLOGY REVIEW | TOLED5 202,36,2011 | |
TOXICOLOGY REVIEW | TXCYAC 307,123,2013 | |
TOXICOLOGY REVIEW | TXAPA9 268,157,2013 | |
TOXICOLOGY REVIEW | MUREAV 802,1,2016 | |
TOXICOLOGY REVIEW | FCTOD7 105,456,2017 |
Standards and Regulations
Organization | Standard | Reference |
---|---|---|
Environmental Protection Agency (EPA) Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) 1988 PESTICIDE SUBJECT TO REGISTRATION OR RE-REGISTRATION | FEREAC 54,7740,1989 | |
Environmental Protection Agency (EPA) Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) 1998 STATUS OF PESTICIDES | Cancelled | RBREV* -,83,1998 |
Mine Safety and Health Administration (MSHA) STANDARD-air | time-weighted average 0.25 mg/m3 (skin) | DTLVS* 3,7,1971 |
Occupational Exposure Limit IN ARGENTINA, BULGARIA, COLOMBIA, JORDAN check ACGIH TLV; | ||
Occupational Exposure Limit IN SINGAPORE, VIETNAM check ACGIH TLV | ||
Occupational Exposure Limit-AUSTRALIA | time-weighted average 0.25 mg/m3, JUL2008 | |
Occupational Exposure Limit-AUSTRIA | MAK-TMW 0.25 mg/m3;KZW 2.5 mg/m3, inhal, skin, 2007 | |
Occupational Exposure Limit-BELGIUM | time-weighted average 0.25 mg/m3, Skin, MAR2002 | |
Occupational Exposure Limit-DENMARK | time-weighted average 0.25 mg/m3, skin, carc, MAY2011 | |
Occupational Exposure Limit-FINLAND | time-weighted average 0.25 mg/m3, short term exposure limit 0.75 mg/m3, skin, NOV2011 | |
Occupational Exposure Limit-FRANCE | VME 0.25 mg/m3, Skin, C3 Carcinogen, FEB2006 | |
Occupational Exposure Limit-GERMANY | MAK 0.25 mg/m3, inhal, skin, 2011 | |
Occupational Exposure Limit-ICELAND | time-weighted average 0.25 mg/m3, skin, NOV2011 | |
Occupational Exposure Limit-KOREA | time-weighted average 0.25 mg/m3, skin, 2006 | |
Occupational Exposure Limit-MEXICO | time-weighted average 0.25 mg/m3;short term exposure limit 0.75 mg/m3 (skin), 2004 | |
Occupational Exposure Limit-NEW ZEALAND | time-weighted average 0.25 mg/m3, skin, JAN2002 | |
Occupational Exposure Limit-NORWAY | time-weighted average 0.25 mg/m3, JAN1999 | |
Occupational Exposure Limit-PERU | time-weighted average 0.25 mg/m3, JUL2005 | |
Occupational Exposure Limit-POLAND | MAC(time-weighted average) 0.5 mg/m3, short term exposure limit 1.5 mg/m3, JAN1999 | |
Occupational Exposure Limit-RUSSIA | time-weighted average 0.01 mg/m3, short term exposure limit 0.03 mg/m3, Skin, JUN2003 | |
Occupational Exposure Limit-SWITZERLAND | MAK-week 0.25 mg/m3, carc 3, inhal, skin, JAN2011 | |
Occupational Exposure Limit-THAILAND | time-weighted average 0.25 mg/m3, JAN1993 | |
Occupational Exposure Limit-THE NETHERLANDS | MAC-TGG 0.25 mg/m3, Skin, 2003 | |
Occupational Exposure Limit-THE PHILIPPINES | time-weighted average 0.25 mg/m3, Skin, JAN1993 | |
Occupational Exposure Limit-TURKEY | time-weighted average 0.25 mg/m3, Skin, JAN1993 | |
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Construction) | 8H time-weighted average 0.25 mg/m3 (skin) | CFRGBR 29,1926.55,1994 |
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Federal Contractors) | 8H time-weighted average 0.25 mg/m3 (skin) | CFRGBR 41,50-204.50,1994 |
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (General Industry) | 8H time-weighted average 0.25 mg/m3 (skin) | CFRGBR 29,1910.1000,1994 |
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Shipyards) | 8H time-weighted average 0.25 mg/m3 (skin) | CFRGBR 29,1915.1000,1993 |
NIOSH Documentation and Surveillance
Organization | Standard | Reference |
---|---|---|
National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO ALDRIN-air | 10H Carcinogen time-weighted average 0.25 mg/m3 (Sk) (0.15 mg/m3 LOQ) | NIOSH* DHHS #92-100,1992 |
National Occupational Exposure Survey 1983 | Hazard Code 04260; Number of Industries 1; Total Number of Facilities 7; Number of Occupations 2; Total Number of Employees Exposed 42; Total Number of Female Employees Exposed 7 | |
National Occupational Hazard Survey 1974 | Hazard Code 04260; Number of Industries 1; Total Number of Facilities 43; Number of Occupations 8; Total Number of Employees Exposed 605 |
Status in Federal Agencies
Organization | Reference |
---|---|
ATSDR TOXICOLOGY PROFILE (NTIS** PB/93/182368/AS) | |
EPA GENETOX PROGRAM 1988, Inconclusive: D melanogaster Sex-linked lethal | |
EPA GENETOX PROGRAM 1988, Negative: Histidine reversion-Ames test; S cerevisiae-homozygosis | |
EPA GENETOX PROGRAM 1988, Positive/limited: Carcinogenicity-mouse/rat | |
EPA TSCA Section 8(d) unpublished health/safety studies | |
EPA TSCA TEST SUBMISSION (TSCATS) DATA BASE, JANUARY 2001 | |
NCI Carcinogenesis Bioassay (feed);clear evidence:mouse | NCITR* NCI-TR-21,1978 |
NCI Carcinogenesis Bioassay (feed);equivocal evidence:rat | NCITR* NCI-TR-21,1978 |
NIOSH Analytical Method, 1994: Aldrin, 5502 | |
On EPA IRIS database |
Page last reviewed: November 16, 2018
Content
source: National Institute for Occupational Safety and Health